New drug baxdrostat offers 24-hour protection for hard-to-treat high blood pressure
High blood pressure (hypertension) remains a leading global health threat — and now a promising new drug, baxdrostat, may offer a breakthrough for patients whose condition is resistant to standard therapies.
A new mechanism targeting aldosterone
Blood pressure is strongly influenced by the hormone Aldosterone, which regulates sodium and water levels in the body. In some patients, excessive aldosterone production causes fluid retention and elevated blood pressure. Traditional medications have blocked aldosterone’s effects, but baxdrostat works differently: it directly inhibits the enzyme aldosterone synthase, reducing production of the hormone at its source.
Trial results show impressive, sustained reductions
In an international Phase III trial known as BaxHTN, nearly 800 participants with uncontrolled or treatment-resistant hypertension — meaning their blood pressure remained high despite taking at least three medications — received baxdrostat or placebo alongside their current therapy. After 12 weeks:
- Patients taking 2 mg baxdrostat saw an average seated systolic blood pressure drop of 15.7 mmHg (placebo-corrected −9.8 mmHg) compared to placebo.
- The effect was consistent throughout the 24-hour cycle — including early morning hours when the risk of heart attack and stroke peaks.
- The drug was generally well-tolerated with no unanticipated safety signals.
Professor Bryan Williams of University College London, principal investigator of the trial, called the results “quite remarkable” both for magnitude and duration of effect. tctmd.com
Why this matters for patients
According to the British Heart Foundation and other health bodies, uncontrolled high blood pressure affects hundreds of millions of people worldwide and significantly increases the risk of heart attack, stroke, kidney disease and early death.
For patients whose blood pressure remains elevated despite multiple drugs, a once-daily pill that works day and night could be a game-changer. The sustained effect offers promise in bridging the gap in current therapy — especially in vulnerable early-morning hours when cardiovascular risk is highest.
Looking ahead: regulatory and clinical implications
The drug’s manufacturer, AstraZeneca, has stated its intention to file for regulatory approval by late 2025 following the successful trial outcome.
Experts caution, however, that while results are very positive, long-term outcomes (such as reduced heart attacks or strokes) still need full evaluation. The drug must also prove cost-effective and accessible globally if its impact is to reach the many millions struggling with resistant hypertension.
“This is a real advance in our understanding of treatment-resistant hypertension and a major breakthrough in new treatment options,” said Prof Williams.
Stay informed and protect your health!
CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for expert tips, health updates, and the latest medical research straight to your phone.